Sorafenib in patients with child-pugh class A and B advanced hepatocellular carcinoma: A prospective feasibility analysis

T. Pressiani, C. Boni, L. Rimassa, R. Labianca, S. Fagiuoli, S. Salvagni, D. Ferrari, E. Cortesi, C. Porta, C. Mucciarini, L. Latini, C. Carnaghi, M. Banzi, S. Fanello, M. De Giorgio, F. R. Lutman, G. Torzilli, M. A. Tommasini, R. Ceriani, G. CoviniM. C. Tronconi, L. Giordano, N. Locopo, S. Naimo, A. Santoro

Research output: Contribution to journalArticle

Abstract

Background: Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. There are few prospective data on sorafenib in patients with HCC and CP class B. Patients and methods: A consecutive prospective series of 300 patients with CP class A or B HCC were enrolled in a dual-phase trial to determine survival and safety data according to liver function (class A or B) in patients receiving oral sorafenib 800 mg daily. [Results of this study were presented in part at the ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012. J Clin Oncol 2012; 30 (Suppl 4): abstract 306.]. Results: Overall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar. Conclusion: Although patients with HCC and CP class B liver function have poorer outcomes than those with CP class A function, data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib.

Original languageEnglish
Article numbermds343
Pages (from-to)406-411
Number of pages6
JournalAnnals of Oncology
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • Carcinoma
  • Child-Pugh class
  • Cirrhosis
  • Hepatocellular
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Sorafenib in patients with child-pugh class A and B advanced hepatocellular carcinoma: A prospective feasibility analysis'. Together they form a unique fingerprint.

  • Cite this